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Introduction 
The meeting was opened by Dr Kevin O'Reilly, Department of Reproductive Heath and 
Research, World Health Organization, Geneva. Dr O'Reilly explained that the meeting was 
the first part of a two-part consultation, which would address dual protection at the global 
level, while the second part would consider dual protection in countries of the former Soviet 
Union and some of the CEE/CIS (Central and Eastern Europe/Commonwealth of 
Independent States) and Baltic States. This latter part was the first of several regional 
consultations planned. 
Since the International Conference on Population and Development (ICPD) in Cairo, there 
has been an expanded mandate in reproductive health. Reproductive health services now face 
the challenge of looking not merely at providing family planning methods, but also 
embracing STI/HIV services as well. A vital part of this integration must be the adoption of 
new policies to promote barrier methods such as the condom, which can prevent both 
pregnancy and STI/HIV infection. The adoption of such a policy will be a challenge for those 
providers who have disregarded the male condom as an effective method of family planning 
for more highly advanced methods which have become available over the past thirty years. 
At present, both semantic and conceptual confusion over the term 'dual protection' persists 
amongst providers and agencies. Though others have made specific definitions in the past, 
many continue to define dual protection either as an outcome or as a method or methods. The 
definition of dual protection was clarified as: a concept defined as the outcome of protection 
against both pregnancy and HIV and other STIs. The promotion of dual protection can vary 
from region to region and can be done by using solely the condom or the condom in 
conjunction with another method. 
Dr Gunta Lazdane, Medical Academy of Latvia, was elected Chairperson, and the provisional 
agenda was adopted. 
Presentations and discussions 
Dr Nef Walker, UNAIDS reviewed the current STI/HIV epidemic worldwide. Globally 4.2% 
of deaths can be attributed to AIDS. In Africa 19% of all deaths are due to HIV/AIDS, 
making it the primary cause of death. Statistics from 1998 showed that sub-Saharan Africa, 
south-east Asia and Latin America were the areas hardest hit by the epidemic, with figures 
ranging from 22.5million, 6.7 million and 1.4 million respectively. In the last few years, the 
area of fastest growth in the epidemic has moved from eastern and central Africa to southern 
Africa. Statistics from South Africa showed that HIV prevalence amongst antenatal care 
(ANC) attendees in South Africa had risen from 0.7% in 1990 to 22.8% in 1998. In 
Botswana, 33% of all women aged 15-35 are infected with HIV. It is believed that the 
prevalence amongst women may be underestimated by up to 20% due to prevalence rates 
being based on antenatal clinics and the chance that HIV positive women are less likely to get 
pregnant. This must be considered when analysing HIV prevalence data.  Page 2    WHO/RHR/01.20 
The proportional increase of HIV infection presents both diverse and shocking statistics, in 
contrast to the actual number of infected cases. The escalating cases of HIV infection in 
countries of the former Soviet Union and some of  the CEE/CIS and Baltic States are 
particularly troubling. The number of infections in Russia has been escalating with more 
cases estimated in the first nine months of 1998 than in the last four years, with pockets of 
growth particularly amongst intravenous drug abusers. In the Caribbean, HIV infection is 
spreading from those in high-risk groups to the antenatal population.  
Dr Ward Cates, Family Health International (FHI), presented statistics showing the chances 
of becoming pregnant and transmitting gonorrhoea or HIV. The chance of a woman 
becoming pregnant mid cycle range from 17-30%. The likelihood of transmitting gonorrhoea 
from male to female is estimated to be 50% and from female to male 25%. The chance of 
transmitting HIV ranges from 1 in 100 at the early and late stages of infection and 1 in 1000 
at other stages. Chances also differ by direction of transmission with a higher probability of 
transmission from men to women. 
Dr Cates described a study by Hooper
1, considering the effectiveness of the condom for the 
prevention of STIs. This study was undertaken amongst 528 US naval seamen on shore leave 
in the Philippines. Of the 29 men who used condoms with each sexual act, none got infected. 
Amongst the non-users 14.2% acquired gonorrhoea. This is just one example of ten studies in 
total demonstrating the effectiveness of the condom for STI/HIV prevention.  
Dr Cates demonstrated the difficulties of finding ultimate protection for disease and 
pregnancy by using the diagram below. The diagram highlights the difficulty of providing the 
client with a method which is equally effective for both pregnancy and disease prevention. 
This has proved and will continue to prove problematic for providers who wish to be able to 
provide the client with the best 
possible method to protect them 
from both. Those methods that 
offer protection against disease 
do not protect well against 
pregnancy and vice versa. The 
octagons show that when 
emergency contraceptive pills 
(ECP) are used as a method of 
contraception alone, they do not 
prove to be as effective as other 
methods for providing effective 
pregnancy prevention. 
This diagram shows that the ultimate goal is to protect against disease and pregnancy. The 
boxes indicate that methods offering high protection against disease do not protect well 
against pregnancy and vice versa. The octagons show that when the emergency contraceptive 
pill (ECP) is used as a method of contraception alone, it is not as effective against preventing 
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pregnancy as other highly effective methods. The crucial question is whether we can prevent 
high rates of STI and dramatically reduce unwanted pregnancies by using the male condom 
with emergency contraception as a backup. The only possibility at present to protect from 
both pregnancy and disease is to use the condom and the ECP as a backup in case of failure 
or misuse.  
Dr Bert Peterson, WHO, next presented fuller data on contraceptive effectiveness, including 
that of the condom. Dr Peterson presented a comparison of contraceptive effectiveness rates 
between the condom and oral contraceptives (OC) with typical use, based on data from the 
U.S. National Survey of Family Growth, analysed by J. Trussell and B. Vaughan
2.  These 
data showed that the rates of unintended pregnancy are similar given typical use of OCs and 
condoms (7% and 9% respectively). Data on the effectiveness of OCs given perfect use are 
often compared to data on the effectiveness of condoms given typical use, which makes the 
difference in effectiveness appear to be greater than it may actually be. Contraceptive failure 
with perfect use of the condom has been estimated at 3%. While this is certainly higher than 
the contraceptive failure rate with perfect pill use (< 0.5%), it is in fact better than the 
contraceptive failure rate with typical pill use. Those methods that are particularly effective 
for pregnancy prevention (Norplant, DMPA, IUDs and sterilization, for example) offer no 
protection against STI/HIV. 
Dr Peterson next presented data on condom effectiveness for disease prevention, drawn from 
studies of HIV serodiscordant couples. In one study in Haiti, a 1% seroconversion rate 
amongst those using a condom was found
3.   In a similar study, amongst HIV infection in 
discordant couples in Italy, 1.1 seroconversions per 100 person years was found amongst 
those always using the condom
4.  It should be noted that in this study those inconsistent users 
of the condom have a higher incidence than never users. The di Vincenzi study, 1994, in 
Europe showed no seroconversions in Europe in 100 person years
5.   
Discussion: 
In the discussion that followed the question of whether hormonal methods of contraception 
raised the risk of STI/HIV infection was raised. The issue was investigated in a study on 
Macaque monkeys, 1996
6. In this study, some females were injected with progesterone and 
others were not. Both of these groups were then given an inoculum of simian 
immunodeficiency virus (SIV) and the results showed that those with progesterone were 
more likely than those without to seroconvert.  
There was also a discussion about microbicides and the important role they may have. 
However, microbicides as well as vaccines, may well be at least a decade away. The need for 
further studies on the male and female condom and their contraceptive efficacy in developing 
countries was also discussed. The most extensive research done to date has been in the 
developed world. Clinical trials examining pregnancy rates in developing countries do not 
currently exist, therefore Demographic and Health Survey (DHS) studies are required. There 
is also a need for additional data on discontinuation rates of the condom.  Page 4    WHO/RHR/01.20 
Dr Karl Dehne, University of Heidelberg, commented that in many parts of the world, such as 
eastern Europe, abortion is still used as the primary method of family planning. Areas where 
family planning services are just becoming established are areas where the integration of 
HIV/STI and family planning services should be of paramount importance.  
Dr Helen Rees, Reproductive Health Research Unit, University of Witwatersrand, South 
Africa suggested the need to consider the effectiveness of condom use in various settings and 
programmatic evidence of where sub-standard condoms are being supplied. The target group 
should be considered when promoting the dual method approach and whether the condom 
should be suggested alone or with another method. Research has shown that the more 
effective the method of contraception the less likely the couple are to use a condom for 
disease prevention alone. It would therefore be unlikely that teenagers would conscientiously 
use two methods correctly. In this case it may be best to suggest condom use to protect 
against both outcomes. It is important to note that once a method has been recommended, 
especially one that requires little further contact with the service provider, counselling on risk 
is reduced. 
The afternoon session began with Dr Ann Duerr, Centers for Disease Control, United States 
of America (USA), reporting on a recent study on the female condom. Dr Duerr reviewed 
studies in which the female condom has been used for both pregnancy and disease prevention 
and factors affecting their use. The use of the female condom for pregnancy prevention in a 
study done by Farr
7 showed that amongst women in the USA the pregnancy rate with typical 
use was 12.4 % over a six-month period and for perfect use, the rate was 2.6%. Amongst 
Latin American women, the pregnancy rate with typical use was 22.2 % over six months and 
with perfect use 9.5% over six months.  
Dr Duerr also reviewed the experiences reported by users of the female condom in a study 
conducted by CDC and the University of Alabama at Birmingham, USA. Most found the 
female condom as an acceptable method but some problems were reported. These included 
leakage problems, pain during use, problems with the inner ring and non-menstrual bleeding. 
Dr Duerr also presented data on the exposure to semen during female condom use. The 
presence of semen in the vaginal vault was established by detecting prostate specific antibody 
(PSA). PSA was detected in 6% to 21% of vaginal swabs collected by women consistently 
using female condoms. The source of the exposure was usually due to slippage and misuse, 
as the condoms seldom broke. Dr Duerr summarized her presentation by suggesting that 
further comparative studies are required doing the same test on the male condom for which 
such studies have not been conducted, before the real importance of these findings can be 
assessed.  
Discussion: 
WHO is currently developing programmatic guidelines for the female condom, which has 
always been regarded as an adjunct to the male condom and not a replacement in national 
programmes, in an attempt to increase user choice. Female condoms may often be bought WHO/RHR/01.20   Page  5 
first as a novelty, as sales peak quickly and then slowly level out. A study undertaken 
amongst 1000 women in Alabama, USA also reflects this: initially a great deal of both male 
and female condoms were used, although most abandoned the female condom and reverted to 
the male condom.  
The female condom is often heralded as a female-controlled method; however, women still 
need the consent, or at least acquiescence, of men to use it. Some studies have even shown 
that men are often the initiators of female condom use. For those cultures or settings where 
men are resistant to male condom use, the female condom may fare no better.  
Cultural barriers to introducing the female condom should be considered. Dr Godfrey 
Tinarwo, Zimbabwe National Family Planning Association, spoke about the difficulties of 
introducing this method into some cultures where it is a cultural taboo for women to insert 
their fingers into their vagina. It was also mentioned that studies have shown that for those 
practising dry sex, the female condom was considered over lubricated.  
Dr Rees described the female condom re-use studies that have been conducted and are being 
analysed. If these studies establish that re-use of the female condom is safe, the cost, a major 
barrier to female condom use, could be significantly reduced.  Re-use of the female condom, 
however, has proved problematic amongst sex workers who have re-used condoms between 
clients.  
Dr Firman Lubis, University of Indonesia, raised the issue of integration and the best way to 
build an alliance between family planning and STI services. The success of family planning 
services should be considered first and these foundations should then be built on. STI 
services and family planning services were compared to kingdoms, as neither should be 
subordinated. The issue is not specifically to bring the two services together but to get them 
to form a working alliance so the client receives the best services possible. Providers must be 
trained sufficiently in family planning, antenatal care and STI/HIV prevention. At present, 
the purchasing, storage and distribution of condoms for STI programmes and family planning 
programmes are often conducted separately, approaches to their provision are not coordinated 
and clients receive contradictory messages of where to go for what services.  Elementary 
integration such as this is feasible and essential. 
Discussion by national programme managers: 
National programme managers discussed the extent of the STI/HIV epidemic in their 
countries. In Uganda, the true extent of the HIV pandemic has been acknowledged. The 
country has had the backing of the President, Government and Church to openly address the 
issues of HIV/AIDS, giving prevention efforts a great deal of credibility and media coverage 
to promote condom use.  Nevertheless, condoms have only become a prominent feature in 
Uganda’s prevention efforts in recent years. 
In Cambodia, the condom has long been a very popular method of family planning. This 
popularity is largely due to affordability; by heavily subsidizing the sale price of condoms, Page 6    WHO/RHR/01.20 
30-40 condoms cost approximately $1. Certain groups such as commercial sex workers have 
been much easier to target than the general population, as may be expected.  
In Namibia, condoms have been difficult to introduce in some areas due to cultural beliefs. 
Many people still believe that the spermicides used in lubricating some condoms can cause 
sterility. At present in Namibia condoms are being used solely for STI prevention; therefore 
projects must be restructured to re-introduce condoms for pregnancy prevention. As in 
Uganda, the STI/HIV prevention programme in Namibia has the full backing of the 
government, and each minister must take an oath to support the programme.  
Dr Rees gave a presentation on the ECP and its relationship to condom acceptability. ECP is 
used as an emergency procedure to prevent pregnancy following unprotected intercourse. Dr 
Rees stressed that this should be a one-time procedure and not a routine contraceptive 
approach. It is to be used for an unexpected single episode of unprotected intercourse either 
due to missed pills or failure to use a barrier method or after a condom has split.  
ECP is multifactorial affecting the endometrium, follicular development, ovulation and early 
luteal function. It is not an abortificient, as it is ineffective once implantation has taken place. 
Therefore ECP must be taken relatively soon after the episode of intercourse to be effective. 
If taken in time, studies have shown that ECP reduces the chance of pregnancy by around 
75%. However, although it is difficult to calculate exactly, it is likely that few women using 
ECP would have become pregnant anyway as less than 35% of women who have intercourse 
mid-cycle will get pregnant even if they do nothing. Therefore of all women who take ECP 
only about 2% of those will get pregnant. Although there are minor side effects that may 
occur with ECP, including headaches, dizziness, menstrual disturbances and breast 
tenderness there have been no serious complications or reported deaths.  
At present there are also many unresolved problems related to ECP. Research is vitally 
needed to understand whether the availability of ECP would discourage consistent condom 
use, encouraging non-barrier method use instead, or actually increase condom use for dual 
protection. Increased availability of ECP may encourage couples to use, or may encourage 
providers to promote condoms for dual protection. How to provide ECP is one of the key 
questions. Given its time-limited benefit, providing ECP to condom users at clinical settings 
may be beneficial. However, this may serve to discredit the effectiveness of the condom, as 
the immediate provision of ECP by clinicians may predict condom failure.  In most 
developed and some developing countries as well, barrier methods are still used and accepted 
as a contraceptive method. In these cases, ECP may provide a potential benefit for condom 
users. However, in high prevalence countries the condom may be used with new partners, 
extramarital relationships and sex workers but are unlikely to be used with husbands or 
wives. Consensus needs to be reached on how we can change the attitudes of providers and 
also the behaviour of clients to realize the benefits of dual protection. WHO/RHR/01.20   Page  7 
Discussion: 
Mr. Jeff Spieler, United States Agency for International Development (USAID), shared 
recent data from the USAID-sponsored study on emergency contraception conducted by the 
Population Council in Zambia. This study showed a decrease in condom use from 41% to 6% 
after ECP use had been introduced. Mr Spieler also mentioned a study undertaken by 
Dr Anna Glasier in Edinburgh, and a study in New York conducted by the International 
Planned Parenthood Federation, on ECPs.  Both of these studies also showed a dramatic 
decrease in condom use in favour of hormonal methods after ECP use. One interpretation 
offered was that following a pregnancy “scare”, clients chose to adopt a contraceptive method 
that they believed would be much more effective than condoms.  
Dr Guy Stallworthy, Population Services International addressed the issue of providers’ 
attitudes as barriers to the promotion of condoms. Dr Stallworthy stated that approximately a 
third of men and women report that they are too shy to seek condoms from health workers. It 
is vital that condoms portray a feeling of sexiness, partnership, virility, youth, quality and 
protection, to rid it of any deep-rooted symbolism that may already be attached to it. Lessons 
could be learned from Zambia and Zimbabwe where marketing of the female condom has 
successfully portrayed a notion of couples and caring. This has been achieved by naming the 
female condom as the contraceptive sheath, and associating it with Johnson and Johnson, a 
company with an image of family products and caring.  
Dr Jayantilal Satia, International Council on Management of Population Programmes, 
Malaysia, gave a presentation on “Managing family planning programmes for dual 
protection”. At present 6-9 billion condoms are manufactured and used, it is assumed, 
annually. However, there is an untapped market that could greatly increase the annual 
condom production. To access this market, Dr Satia advocated giving  a high priority to 
redefining programmes and services, social marketing, male clinics and mobilizing finances. 
To reach and involve men there should be identification of target groups, research as a basis 
for programming, and strategies to meet community information needs for example IEC, 
advocacy and counselling.  
Professor William Fisher, University of Western Ontario, Canada, gave a presentation 
entitled “All together now: Condoms oral contraceptives and reproductive health”, 
concerning the relationship of condom use, oral contraceptive use and reproductive health 
outcomes. Professor Fisher spoke about the findings of a research programme he and his 
colleagues have undertaken to identify barriers to condom use. Three particular areas of 
concern emerged: information deficits, motivational obstacles and behavioural skills.  
Limitations, which presently impede condom use, favour oral contraceptive use and result in 
diminished condom use and increased STI risk.  
This presentation considered the correlation between oral contraceptives (OCs) and condom 
use. Research in Canada and the USA has shown that with the increase in the number of 
sexual partners, condom use actually decreases and OC use increases. It appears that in these Page 8    WHO/RHR/01.20 
cases pregnancy prevention is given a higher priority than the prevention of STI infection, as 
the use of OCs affords no protection against infection. Significantly, and as expected, as 
condom use declines with increasing numbers of partners, STI diagnoses increased 
dramatically.   
OCs are an easy and effective way to avoid likely, immediate and negative events such as 
pregnancy. Among providers, attitudes to OCs tend to be positive whereas attitudes towards 
condoms may be negative and even stigmatized. It is imperative that we retrain ourselves first 
and realize that prescribing OCs is now, in many places, portal to increased STI/HIV risk.  A 
study undertaken by Macdonald
8  regarding high risk STI/HIV behaviour among female 
college students in Canada showed that, as the number of sexual partners increased, the 
number using condoms dropped drastically, from 20% regular users for 1 sexual partner to 
8% regular users for those who have had 10 or more sexual partners. Conversely, in this 
group 85% were regular users of oral contraceptives while in the group with one sexual 
partner only 66% were OC users.  
The data showed a strong trend with the more sexually active women, in terms of numbers of 
partners, being more likely to use OCs and less likely to use condoms. Dr Fisher concluded 
that these data revealed a provider bias for pregnancy prevention, unfortunately at the 
expense of STI/HIV prevention. Not surprisingly, the percentage of women with a history of 
STI correlated positively with partner numbers and OC use and negatively with condom use. 
In a study by Misovich, Fisher and Fisher
9, 66% of couples at the beginning of a relationship 
used condoms; however over time, concern about infection diminished and 66% of condom 
users changed to OCs. Professor Fisher demonstrated how messages given by the providers to 
the clients may be translated into risky behaviour. Few sexual partners over a relatively short 
time may result in many partners over an extended period. Concern about getting to know the 
partner and their sexual history provides an entirely false sense of security and is not 
diagnostic of STI/HIV risk.  Public health advice to the effect that one partner is “safe” may 
actually provoke STI/HIV risk exposure if, as is often the case, the “one partner” is part of a 
serially monogamous pattern in which single partners B and STI/HIV risk B accumulate over 
time.  Getting to know a partner and his or her sexual history is also an exercise that may feel 
safe but is often entirely nondiagnostic of STI/HIV risk.  Providers and patients who feel that 
getting to know a partner or his or her sexual history is a form of safer sex may be provoking 
unsafe sexual behaviour.  
Often for the provider and the client, the most immediate consequence of sex is pregnancy 
and therefore pregnancy prevention takes the priority when a method of contraception is 
recommended. The easiest and most effective methods of contraception, such as OCs, are 
coitus independent, effective and more aesthetically pleasing to use than the condom. 
Furthermore, it is much easier for the provider to write a prescription for OCs than to address 
the issue of STI/HIV with the client and probably encounter resistance. The burden for the 
client is also great, as here she must convince her partner to initiate condom use and to 
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Completely balanced, informed choice can only be assured if providers themselves change 
their own attitudes and norms and seriously consider dual protection, not just pregnancy 
prevention. The vital message B crucial for informed consent but not usually given to clients 
at present B is that using OCs instead, or without the addition, of condoms may greatly 
increase the chance of a client contracting a sexually transmitted infection. Providers and 
clients must both improve their ability to discuss, negotiate, initiate and maintain both 
pregnancy and STI/HIV prevention. One possibility, being tested currently in research in 
Canada, is to prescribe OCs and condoms for a trial period of three months.  At that point, the 
client returns for an STI/HIV test and counselling and for discussion about the advisability of 
ceasing condom use at the next visit.  
Discussion: 
In the ensuing discussion, Professor Fisher commented that in many cases women do have 
power in a relationship and that the extremes to which men would go to gain sexual access 
are often underestimated.  Dr Grace Delano, Association for Reproductive and Family 
Health, Nigeria, mentioned socioeconomic factors and that in many instances the woman will 
be unable to afford a back-up method of contraception along with her main method. 
Furthermore, the importance of family planning must also not be overlooked for those 
women for whom abortion is not an option, either for religious, legal or personal reasons. An 
additional concern raised was the fact that high STI/HIV settings are often settings where 
there is high maternal mortality, so the risk associated with unplanned pregnancy may be 
even higher. In these cases, effective family planning is essential otherwise women would be 
at risk of both STI/HIV infection and serious complications with an unwanted pregnancy.  
Discussion groups 
Common views and approaches to policies: 
Small group discussions on how to implement dual protection were held and participants 
were split into three groups to discuss these topics. 
One group discussed how best to implement dual protection in family planning programmes 
and how to change providers’ attitudes. The groups recommended that programmes need to 
target men, women and sexually active youth through existing services. However, new 
programmes should be created as well and integrated to combine the efforts of both family 
planning and STI/HIV prevention. The specific kind of intervention may depend on services 
doing the targeting and on groups targeted. The group also recommended that priority is 
given to changing attitudes of programme providers by providing complete information about 
STI/HIV, informed choice and IEC. Advocacy for policy change to include all available 
methods of barrier contraception (including condoms and diaphragms) in family planning 
services was also seen as a priority. It is also important that sexually-active youth, both 
married and unmarried, have increased access to services that provide dual protection and 
that condoms are visible and available to the public through a variety of channels, including 
vending machines and brothels.   Page 10    WHO/RHR/01.20 
The group also considered it important to advocate for policy change to increase the priority 
given to promoting and making available all methods of barrier contraception, including 
condoms and diaphragms, in family planning programmes. Any existing barriers that prevent 
sexually active youth from accessing services, or obtaining barrier methods, particularly 
condoms, must be removed. Cost was also identified as an important issue: who will pay and 
how much will they pay? The group also highlighted the lack of emphasis placed on dual 
protection by the international and technical agencies active in the area and called for greater 
coordination of support and uniformity of policies and guidelines across the agencies.  
Service delivery must also be met by a variety of settings, not just public sector but including 
social marketing as well. There must be a greater visibility and availability of condoms. In 
this context, the sale of condoms through vending machines was specifically mentioned. 
Barrier methods are often not suggested or promoted for contraceptive use due to providers’ 
attitudes, which can be influenced by several factors. These may include: information or 
misinformation about STIs; policy; client and community attitudes; a provider’s own 
background, past practices, and perceptions about condoms as a family planning method; and 
judgmental attitudes towards unmarried individuals or those infected with STI/HIV.  Other 
issues identified as important by the group included: poor quality of care, especially 
counselling and lack of user-friendly services; poor partner referral; training for family 
planning providers, including facts about STI/HIV; information and counselling for practical 
steps to condom use including the use of models and videos; the reinforcement and 
promotion of barrier methods through supervision and satisfied users as role models; gender 
and sexuality. Interventions should stimulate condom use by focusing on desirable attributes. 
How to reposition condoms in providers’ minds and behaviour is a question of paramount 
importance. Changes in client and community attitudes can be facilitated by high level 
political commitment, by desirable role models for different target groups, by professional 
IEC campaigns and by better packaging and quality control of the image given to condoms. 
Providers need research on user behaviour and need to address specific target groups 
including those who are infected with HIV. The group also suggested some issues for 
research at country level, including quality of care, access to services, provider attitude and 
quality of the provision of the condom, either male or female.  There should be research on 
the nature of use as well: who uses condoms? how do people use condoms? and is it used 
correctly and consistently? The research agenda should also include introduction research on 
the female condom with wider access and availability. 
The second discussion group considered the issue of targeting for dual protection: which 
groups should be targeted, how to target various groups and under what conditions. The 
group considered the cases of Bangladesh, Kenya and Russia as examples of countries with 
different STI/HIV epidemic profiles but where work could nevertheless be done immediately. 
In Bangladesh, family planning services should involve men, and in particular, should target 
those who are mobile; STI programmes should be expanded to meet men, especially in the 
private sector.  Sex workers, along with adolescents, should also be targeted, with particular WHO/RHR/01.20   Page  11 
attention to boys and young men. Condoms should also be promoted through community 
groups.  
In Kenya, it was suggested that raising the awareness of risk would increase the promotion of 
the condom as a method of family planning; providers should be accurately informed about 
all methods and dual protection. If women are unable to negotiate exclusive, consistent 
condom use, then two methods should be suggested, with the female client suggesting a 
primary contraceptive method choice. In the case of male patients, all programmes should 
target clients with messages about dual protection, including the condom. Family planning 
clinics should be strengthened to reach adolescents through outreach, peer education, school 
counselling, service referral and to promote condom use.  
In Russia, clients must be offered a high standard of quality of care and high quality 
counselling, particularly post abortion care counselling.  Family planning services should 
increase their outreach to adolescents, with particular attention paid to condom social 
marketing. STI services are currently only providing care; they should also be focusing on 
prevention, counselling and condom promotion to men. 
The third group discussed the role that emergency contraception could play in the context of 
dual protection and whether ECP should be promoted within a method mix framework. Based 
on existing evidence, ECP should be offered as a backup to any user dependent method, not 
just the condom. From this perspective therefore nearly all methods of contraception could 
benefit from the additional promotion of ECP. Clients should be provided with complete 
information to allow fully informed choice. Service providers should be able to provide 
balanced information to clients and help them to make assessments of their risk to both 
pregnancy and infection.  Clients who choose a method other than condoms should be 
encouraged to use two methods. When discussing condoms, there should be emphasis on 
their effectiveness against both pregnancy and infection when properly used.  Information 
and education should extend beyond the clinical setting, safer sex should be promoted, 
including information on condoms and ECP. When ECP is provided, counselling should also 
be given. Efforts should be made to ensure access to ECP, for those who wish to have ECP as 
a contraceptive option, which would involve assessments of the local situation and necessary 
practical steps to be taken. The aim is to have ECP easily available and accessible, for 
example over the counter.  
Research needs in the case of ECPs should include how to promote and provide the condom 
and ECP; how providers can educate clients for proper condom use, how to make dual 
methods work if that is the client’s choice, and how to introduce ECP without affecting 
acceptability and use of other regular methods? These questions must be assessed and 
addressed locally. The aim must be to make ECPs easily available (e.g. over the counter) in 
the most beneficial and least harmful manner.  
Discussion groups focused again on the themes of: research priorities for dual protection; the 
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and what countries with a high prevalence of STI/HIV have done or need to do to implement 
dual protection. 
Research priorities 
The group responsible for research produced a robust research agenda. The major areas for 
research listed were:  
  Lack of information on use effectiveness of male condoms in developing countries 
  How can providers educate clients about consistent condom use and how to negotiate it 
(perhaps building on experience of commercial sex workers who have been able to 
negotiate 100% use) 
  Operations research in different cultural environments concerning condom use (best 
operational approaches to promote condoms for consistent, correct, continuous use) 
  Modelling of effectiveness and public health impact of consistent condom use on: STI, 
HIV, unsafe abortion and maternal mortality in different service environments and under 
different conditions 
  Effects of ECP on use of other methods, particularly barrier methods 
  Effectiveness of the condom plus ECP for pregnancy prevention  
  Physiological effects of more frequent  (more than twice per year) use of ECP 
  How to introduce and provide ECP and for whom 
  How to make dual methods work (for whom and under what conditions) and prevent 
discontinuation of condoms as a secondary method when two methods are chosen 
  Microbicide research 
Three categories of research were identified: biomedical, operations/programmatic and 
behavioural research. Biomedical research should include research on microbicides and the 
improvement in design of both the male and female condom to make them more effective, 
acceptable and cheaper. Operations/programmatic research should include how to train 
family planning programme managers and providers (clinical, community-based providers, 
etc) to manage the dual protection needs of clients, including provider attitudes. Research is 
needed on the impact of quality of care on the use of dual protection and the development and 
treatment of effective gender-specific strategies to increase male and female condom use, 
specifically for men and adolescents. New methods of mass media and other forms of 
communication must be tested. The development and evaluation of communication strategies 
for behaviour change to focus on dual protection must be culturally specific. A research WHO/RHR/01.20   Page  13 
agenda also needs to consider how to introduce and promote ECP without decreasing the 
effectiveness of dual protection and condom use.  
Behavioural research should be conducted to consider under what circumstances clients 
would accept dual protection using two methods. Interventions to increase dual method use as 
well as to increase correct and consistent condom use should be developed and evaluated. 
There should be a priority as well on intervention relevant research on both psychological and 
social factors that drive risk and risk reduction behaviours. Research should also consider 
“successful” trends, programmes and individuals to deduce essential components of that 
success. 
The role of international and bilateral partners  
The consultation then considered issues of implementation and what was needed to move 
ahead. One key suggestion was the perceived need for a joint policy statement that would 
clearly articulate the policies of the key international actors. A key point considered in 
drawing up the joint statement was when to promote dual protection.  
The following points were proposed for inclusion:  
  High contraceptive prevalence B the promotion of double methods 
  Low contraceptive prevalence, depending on AIDS profile B promotion of single method 
  Adolescents B promote condoms regardless. 
A draft joint policy statement was produced by a small drafting group and submitted to the 
whole consultation. Included in the draft statement was the importance of national 
governments and family planning policy-makers to respond to the realities of the STI/HIV 
epidemic by expanding the mandate of family planning programmes to focus also on 
prevention of sexually transmitted infection. Informed choice, an essential element of family 
planning programmes, should include the provision of expanded information to assure 
clients’ understanding that the most effective methods of contraception do not protect against 
STI/HIV. It is therefore incumbent on governments and family planning programmes to 
ensure that service providers understand that when used consistently and correctly, condoms 
can provide effective protection against both pregnancy and disease. This information should 
be provided to enable those who are sexually active and at risk to decide whether to use 
condoms alone for dual protection or in conjunction with another contraceptive method.  The 
draft joint policy statement was approved after modification and recommended for 
submission to the policy representatives of the agencies present. 
The meeting produced recommendations strongly endorsing dual protection, defined as the 
prevention of two undesirable outcomes, and affirmed that this can be achieved by correct 
and consistent condom use alone in many cases.  Dual protection must be seen in the context 
of informed choice, one of the basic tenets of family planning programmes, and that informed Page 14    WHO/RHR/01.20 
choice must be recast to include the provision of all complete and relevant information for 
clients, not just information on the prevention of unwanted pregnancy. The co-sponsoring 
agencies were asked to issue a joint statement to this effect for countries to use in family 
planning programmes. International and bilateral agencies were called upon to harmonize 
their approaches to the issue of dual protection, both within and between agencies. The 
consultation recommended that each country must decide who should be especially advised 
to undertake dual protection based on an understanding of the epidemiology of STI/HIV, 
unwanted pregnancy, use patterns for family planning services, availability and use of other 
important services. Assistance was requested from international and bilateral agencies in 
implementing dual protection, starting with assistance for policy advocacy and extending to 
logistics and supply of quality condoms to make it possible. The consultation advocated for 
expanded research efforts to address some key questions, which if answered would greatly 
facilitate countries in their incorporation of dual protection strategies into national agendas.  
Conclusion  
The meeting was drawn to a close. Dr O’Reilly thanked the participants for their 
contributions to this vitally important global consultation on dual protection.  
Recommendations  
The consultation: 
1. Strongly endorsed dual protection as an important priority for family planning 
programmes.  Dual protection was defined as the simultaneous prevention of STI/HIV 
infection and unwanted pregnancy.  It was further concluded that dual protection can be 
achieved in several ways, including the exclusive correct and consistent use of the condom or 
the simultaneous use of two methods – one of which must be the condom.  
2. Recognized that dual protection must be seen in the context of informed choice, one of the 
basic tenets of family planning programmes, and that informed choice must be fully 
implemented to include provision of all relevant information not only on risks for unwanted 
pregnancy but also on risks of STI/HIV risks. 
3. Urged the agencies co-sponsoring the consultation to issue a joint policy statement to this 
effect for countries to use in directing or redirecting the efforts of their family planning 
programmes. 
4. Called upon international agencies, bilateral agencies, national governments and national 
family planning and STI/HIV programmes to co-ordinate their approaches to dual protection, 
both within and between agencies.  
5. Recommended that each country must decide who should be especially advised to consider 
dual protection, and which approach to dual protection to consider, based on an 
understanding of the epidemiology of STI and/or HIV, unwanted pregnancy, and patterns of 
use for family planning methods and services.  Nevertheless, it was agreed that adolescents WHO/RHR/01.20   Page  15 
should be given high priority in any country’s consideration of dual protection.  Furthermore, 
new efforts to reach men are critical as they are essential for successful condom use required 
for dual protection.  Men should be targeted by family planning providers and through other 
activities as well.  
6. Requested assistance to countries from international and bilateral agencies in shifting the 
orientation in family planning programmes to emphasize dual protection and assistance in 
implementing the activities that would follow. This would start with assistance for policy 
advocacy and extend to logistics and supply of quality condoms in countries where the 
burden of STI/HIV is high.  
7. Advocated for an expanded research agenda to address key questions which when 
answered will facilitate countries’ efforts to promote dual protection into their national family 
planning and STI/HIV priorities and programmes. Page 16    WHO/RHR/01.20 
Annex 1. Joint WHO/UNAIDS/UNFPA policy statement 
A consultation of international experts and representatives of international agencies (WHO, 
UNFPA, UNAIDS), international NGOs (IPPF), bilateral agencies (DFID, USAID, GTZ, 
Department of Social and Institutional Development, Ministry of Foreign Affairs, The 
Netherlands) and national family planning and STI/HIV programmes was convened at the 
headquarters of the World Health Organization in Geneva, 21-23 October 1999. On 1 
December 2000, the following policy statement was issued by UNAIDS, UNFPA and WHO: 
JOINT WHO/UNAIDS/UNFPA STATEMENT: 
DUAL PROTECTION AGAINST UNWANTED PREGNANCY 
 AND SEXUALLY TRANSMITTED INFECTIONS, INCLUDING HIV 
Family planning programmes have made significant progress in the provision of 
contraception to reduce unwanted pregnancies.  However, sexually transmitted infections 
(STIs), including HIV, continue to spread rapidly throughout the world, especially in 
developing countries.  This includes the transmission of HIV from mother to child in pre- and 
post-natal settings.  Given this reality, prevention of these infections must be reinforced in the 
context of the provision of information and services for reproductive health, including family 
planning and sexual health, and the concept of dual protection, i.e., protection against both 
unplanned pregnancy and STIs/HIV, must be greatly expanded. 
Reproductive health programmes should include, where necessary, and  should strengthen, 
where already available, components regarding the prevention of HIV and other STIs; while 
continuing to provide services to reduce unwanted pregnancy and maternal mortality. In this 
regard, informed choice on contraception must include the understanding that many methods 
(e.g., hormonal methods of contraception, intrauterine devices and sterilization) that are all 
highly effective against pregnancy, offer no protection against STIs or HIV.  Informed choice 
must also include the acknowledgement that the condom, when used correctly and 
consistently, not only prevents HIV and STIs, but can also be a highly effective 
contraceptive. 
Making sex safer is a concern of all communities, including the global community. For those 
working in the sexual and reproductive health field, the question is how best to promote safer 
sex.  Governments and both public and private reproductive health programmes must ensure 
that service providers and users understand condom effectiveness.  They must provide 
appropriate information about dual protection and take action to enable those who are 
sexually active and at risk to use one or more methods that will give them this dual 
protection.  
Dual protection is particularly important for: 
  sexually active young people between the ages of 15 and 24 who constitute over half of 
newly acquired  HIV infections; WHO/RHR/01.20   Page  17 
  men and women who put themselves and their partners at risk because of their own high-
risk sexual behaviour; 
  sexually active people in settings where the prevalence of STIs or HIV or both is high; 
  sex workers and their clients; 
  women or men who are at risk because of the high-risk sexual behaviour of their partners; 
and 
  those who have a STI and/or HIV, and their partners (preventing transmission to others or 
reinfection is a high priority). 
The International Conference on Population and Development (ICPD), and the recent ICPD + 
5 review, clearly identified family planning and HIV/AIDS prevention as two major 
priorities, setting clear quantitative goals and benchmarks for their achievement. The further 
operationalization of dual protection will require a number of actions by governments, 
international agencies and reproductive health programmes, including : 
  maximizing the integration of family planning and STI/HIV prevention services; 
  training and retraining of service providers and counsellors on dual protection so that 
clients can make free and informed decisions; 
  ensuring availability of condoms at service delivery points, and other outlets; 
  a focus on young people, both boys and girls; 
  a focus on men as the users of condoms; 
  the appropriate introduction of female condoms into reproductive health programmes; 
  incorporation of dual protection into prevention of mother to child transmission of HIV 
programmes; and, 
  the continuing support of research to bring a female-controlled microbicide to the market. 
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